Phase I study of oral azacitidine plus salvage chemotherapy in relapsed/refractory diffuse large B-cell lymphoma

Brian Hess, Nina D. Wagner-Johnston, Lindsey Hendrickson, James A. Davis, Elizabeth Hill, Anshu Giri, Kent Armeson, Maria V. Revuelta, Shanta Salzer, Robin Klingenberg, Leandro Cerchietti · 2026

Read Phase I study of oral azacitidine plus salvage chemotherapy in relapsed/refractory diffuse large B-cell lymphoma by Brian Hess, Nina D. Wagner-Johnston, Lindsey Hendrickson, James A. Davis, Elizabeth Hill, Anshu Giri, Kent Armeson, Maria V. Revuelta, Shanta Salzer, Robin Klingenberg, Leandro Cerchietti (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13538234.txt.

Description

Brian Hess and colleagues run a phase I safety study adding an oral methylation drug to salvage chemotherapy for returned large B-cell lymphoma in a 2026 report. Faulty gene silencing helps lymphoma resist chemotherapy, and the added drug aims to reverse that silencing. Transplant-ready patients received standard salvage drugs plus oral azacitidine at two dose levels under a classic dose-climbing design. Nine patients took part across the dose groups.

Baseline details show most patients relapsed within a year of first treatment, spanning several lymphoma subtypes. Dose records track missed azacitidine doses blamed on low blood counts, most often at the higher dose level. The report centers on safety and workability of the pairing rather than cure rates. The authors frame the combination as a step toward testing whether gene reawakening restores drug sensitivity.

Catalog record

CREATORBrian Hess, Nina D. Wagner-Johnston, Lindsey Hendrickson, James A. Davis, Elizabeth Hill, Anshu Giri, Kent Armeson, Maria V. Revuelta, Shanta Salzer, Robin Klingenberg, Leandro Cerchietti
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE16455
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13538234

Browse the full library · About the Tower of Babel